Phase 3 N=198 An Open-Label Study to Evaluate the Safety of NP101 in the Treatment of Acute Migraine Over 12 Months
Migraine Disorders
Primary: Subject Self-examination of Skin Irritation — 1.0 scores on a scale
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=9,326 A Comparison of Prasugrel and Clopidogrel in Acute Coronary Syndrome Subjects
Acute Coronary Syndrome
Primary: Percentage of Participants With a Composite Endpoint of Cardiovascular (CV) Death, Myocardial Infarction (MI), or Stroke — 10.06; 24.64; 10.96; 24.13 percentage of…
Phase 3 N=569 A Fixed Dose Study of 323U66 SR in the Treatment of Major Depressive Disorder (MDD)
Depressive Disorder, Major
Primary: Change From Baseline in the Montgomery-Asberg Depression Rating Scale (MADRS) Total Score at Week 8/Withdrawal — -13.9; -14.4; -12.9 Scores on a scale — p=0.853
Phase 3 N=267 Safety and Effectiveness of Open-Label Clobazam in Subjects With Lennox-Gastaut Syndrome
Lennox-Gastaut Syndrome
Primary: Median Percent Reduction in Average Weekly Rate of Drop Seizures Based on the 7-day Assessment — 92.3 percentage of drop seizures
Phase 3 N=153 Misoprostol for Treatment of Fetal Death at 14-28 Weeks of Pregnancy
Intrauterine Fetal Demise
Primary: Successful Expulsion of Fetus and Placenta Within 48 Hours — 60; 47 participants — p=<0.05
Phase 3 N=2,144 A Study to Assess the Efficacy, Safety and Tolerability of Once-daily (q.d.) QVA149 in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
Chronic Obstructive Pulmonary Disease (COPD)
Primary: Trough Forced Expiratory Volume In One Second (FEV1) After 26 Weeks of Treatment — 1.45; 1.38; 1.36 Liters
Phase 3 N=100 Efficacy of Nitazoxanide in the Treatment of Chronic Hepatitis C Virus (HCV)
Chronic Hepatitis c
Primary: Sustained Virologic Response — 24; 25 participants
Phase 3 N=198 Gemcitabine/Irinotecan/ZD1839 vs Paclitaxel/Carboplatin/Etoposide/ZD1839 in Carcinoma of Unknown Primary Site
Neoplasms, Unknown Primary
Primary: Overall Survival (OS), the Length of Time, in Months, That Patients Were Alive From Their First Date of Protocol Treatment Until Death — 7.4; 8.5 months
Phase 3 N=80 Effect of Pterostilbene on Cholesterol, Blood Pressure and Oxidative Stress
Hyperlipidemia · Blood Pressure · Oxidative Stress
Primary: LDL — 19.67; 20.04; 5.33; 0 mg/dL
Phase 3 N=518 Safety of Besivance™ (Besifloxacin Ophthalmic Suspension) 0.6% Compared to Vehicle
Bacterial Conjunctivitis
Primary: Ocular Treatment Emergent Adverse Events — 3; 3; 1; 1 Events
Phase 3 N=1,008 Individualizing Dual Antiplatelet Therapy After Percutaneous Coronary Intervention - The IDEAL-PCI Registry
Platelet Inhibition · Coronary Stent Implantation
Primary: Definite Stent Thrombosis — 1; 0 participants
Phase 3 N=261 Study FFR116364, a Placebo-controlled Study of GW685698X in Paediatric Subjects With Perennial Allergic Rhinitis
Rhinitis, Allergic, Perennial
Primary: Mean Change From Baseline in the 3 Total Nasal Symptom Score (3TNSS) Over the Entire Treatment Period — -1.98; -0.89 Scores on a scale — p=<0.001
Phase 3 N=327 Study To Evaluate Patient Preference, Satisfaction And Efficacy Of a Nasal Aerosol Versus an Aqueous Nasal Spray
Perennial Allergic Rhinitis
Primary: Total Preference Composite Score Assessed at the End of the Study. The Total Preference Score is the Standardized Sum of 17 Individual Preference Items — 68.3 scores on…
Phase 3 N=136 Comparison of Oral Valganciclovir and Placebo for the Prevention of Cytomegalovirus (CMV) After Lung Transplantation
Cytomegalovirus Infections
Primary: Incidence of CMV End Organ Disease — 21; 1 participants
Phase 3 N=140 Comparison of Sugammadex With Neostigmine During Laparoscopic Cholecystectomy or Appendectomy (P05699)
Anesthesia, General
Primary: Time From Start of Administration of Investigational Medicinal Product (IMP, Sugammadex or Neostigmine) to Recovery of the Fourth Twitch/First Twitch (T4/T1) Ratio to…